Whitehawk Therapeutics (WHWK) Cash & Current Investments (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Cash & Current Investments data on file, last reported at $211.3 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 8.57% year-over-year to $211.3 million in Q1 2026; TTM through Mar 2026 was $211.3 million, a 8.57% decrease from a year earlier, with the FY2025 full-year figure at $145.7 million, up 208.44% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $211.3 million, up from $145.7 million in the prior quarter.
• Over the last five years, Cash & Current Investments for WHWK reached as high as $231.1 million in Q1 2025 and fell as low as $47.2 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $136.6 million across 5 years, with a median of $134.9 million in 2023.
• Across the five-year window, Cash & Current Investments surged 232.87% in 2022 and sank 56.6% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $172.6 million in 2022, then tumbled by 36.92% to $108.8 million in 2023, then sank by 56.6% to $47.2 million in 2024, then surged by 208.44% to $145.7 million in 2025, then soared by 44.99% to $211.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $211.3 million in Q1 2026, $145.7 million in Q4 2025, and $162.6 million in Q3 2025.